NCT04971590Completed
Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis
LUNELORD: A Descriptive, Prospective Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and QoL of Patients With LUpus NEphritis and Long-term ORgan Damage
Source: ClinicalTrials.gov · Last updated 22 Jan 2026
Brief summary (registry, in English)
This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates \[UAE\], Qatar, Bahrain, Kuwait and Oman).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 193 (actual)
- First submitted
- 12 Jul 2021
- Start date
- 14 Sept 2021
- Primary completion date
- 31 Oct 2024
- Lead sponsor
- GlaxoSmithKline
- Diseases
- Lupus (SLE)
- NCT number
- NCT04971590
What you commit to
- Study type: Observational
- Participants enrolled: 193
- From 14 Sept 2021 to the primary completion date, 31 Oct 2024
- 6 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current or medical history of: a. Congenital or acquired immunodeficiency. b. Malignancy in active treatment phase. c. Acute viral infection, such as human immunodeficiency virus (HIV) infection, requiring hospitalization.
Lab values
- Incomplete medical records to be able to assess the disease severity or absence of any of the following renal laboratory results from the medical record within the last twelve months: a. Urinary protein to creatinine ratio (UPCR) or 24-hour proteinuria or urine sediment (activity). b. Serum creatinine or estimated glomerular filtration rate (eGFR); or measured glomerular filtration rate (GFR), if eGFR is not available.
Who the study is looking for
- More than or equal to 18 years of age
- Clinician diagnosed LN participants.
- At least one visit to the investigational center during 12 months prior to the baseline visit, recorded in medical documentation.
- Literacy in English or Arabic allowing to fully comprehend the written informed consent and study-specific patient reported questionnaires.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Abu Dhabi | United Arab Emirates | Unknown status |
| - Coordinator of this site? Confirm its status | Al Ain City | United Arab Emirates | Unknown status |
| - Coordinator of this site? Confirm its status | Dubai | United Arab Emirates | Unknown status |
| - Coordinator of this site? Confirm its status | Shweikh | Kuwait | Unknown status |
| - Coordinator of this site? Confirm its status | Bawshar | Oman | Unknown status |
| - Coordinator of this site? Confirm its status | Alrayyan | Qatar | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.